A Phase 2 interventional study of BI 655066 and BI 655066 in Psoriasis, sponsored by Boehringer Ingelheim. Completed at 32 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-09-19.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.
Among the 30 studies testing risankizumab in Psoriasis, this one is the 15th largest by enrollment, is one of 2 that started in 2014, is one of 4 in phase 2, and was the 2nd registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 162 across the 30 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 7 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
20 studies in Psoriasis by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 19 finished, 14 (74%) have results posted.
Among the 20 studies in Psoriasis by Boehringer Ingelheim, this one is the 6th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2014, is one of 10 in phase 2, and was the 3rd registered.
Boehringer Ingelheim’s Psoriasis studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing risankizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 20 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
With regards to tuberculosis the following applies:
Have signs or symptoms suggestive of current active or latent TB upon medical history, physical examination and/or a chest radiograph (both posterior-anterior and lateral views, taken within 3 months prior to the first administration of study drug and read by a qualified radiologist).
Have history of latent or active TB prior to screening, except for patients who have documentation of having completed an adequate treatment regimen at least 6 months prior to the first administration of study agent.
Have positive IGRA testing (QuantiFERON-TB Gold) within 2 months prior to or during screening, in which active TB has not been ruled out, except for patients with history of latent TB and documentation of having completed an adequate treatment regimen at least 6 months prior to the first administration of study agent.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BI 655066 s.c.
Drug: BI 655066
BI 655066 s.c.
Drug: BI 655066
BI 655066 s.c.
Drug: BI 655066
Ustekinumab s.c.
Drug: Ustekinumab
Medium dose
High dose
Low dose
Achievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 12
Percentage of participants who achieved ≥90% reduction from baseline in Psoriasis Area and Severity Index score (PASI90) at Week 12. PASI score ranges from 0 (best) to 72 (worst).
Time frame: Baseline and Week 12
Achievement of ≥75% Reduction From Baseline in PASI Score (PASI75) at Weeks 12 and 24
Percentage of participants who achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index score (PASI75) at Weeks 12 and 24. PASI score ranges from 0 (best) to 72 (worst).
Time frame: Baseline, Week 12 and Week 24
Achievement of 100% Reduction From Baseline in PASI Score (PASI100) at Week 12
Percentage of participants who achieved 100% reduction from baseline in Psoriasis Area and Severity Index score (PASI100) at Week 12. PASI score ranges from 0 (best) to 72 (worst).
Time frame: Baseline and Week 12
Achievement of ≥50% Reduction From Baseline in PASI Score (PASI50) at Week 12
Percentage of participants who achieved ≥50% reduction from baseline in Psoriasis Area and Severity Index score (PASI50) at Week 12. PASI score ranges from 0 (best) to 72 (worst).
Time frame: Baseline and Week 12
Achievement of PASI90 at Week 24
Percentage of participants who achieved PASI90 at Week 24. PASI score ranges from 0 (best) to 72 (worst).
Time frame: Week 24
Percentage Change in PASI Score From Baseline at Week 12
Percentage change in Psoriasis Area and Severity Index (PASI) from baseline at Week 12. PASI score ranges from 0 (best) to 72 (worst).
Time frame: Baseline and Week 12
Achievement of sPGA Clear or Almost Clear at Week 12
Percentage of participants who achieved static Physician Global Assessment (sPGA) clear or almost clear at Week 12. sPGA is assessed on a six-point scale from 0 (clear) to 5 (severe).
Time frame: Week 12
Time to Loss of PASI50 Response
Time to loss of PASI50 response.
Time frame: From first drug administration until end of follow-up period, up to 48 weeks
| Milestone | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | Stelara |
|---|---|---|---|---|
| Started | 43 | 41 | 42 | 40 |
| Completed | 39 | 39 | 40 | 39 |
| Not completed | 4 | 2 | 2 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Other reason | 2 | 1 | 2 | 0 |
Percentage of participants who achieved ≥90% reduction from baseline in Psoriasis Area and Severity Index score (PASI90) at Week 12. PASI score ranges from 0 (best) to 72 (worst).
| Percentage of participants | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | BI 655066 90+180 mg | Stelara |
|---|---|---|---|---|---|
| Achievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 12 | 32.6 (19.1 to 48.5) | 73.2 (57.1 to 85.8) | 81.0 (65.9 to 91.4) | 77.1 (66.6 to 85.6) | 40.0 (24.9 to 56.7) |
Percentage of participants who achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index score (PASI75) at Weeks 12 and 24. PASI score ranges from 0 (best) to 72 (worst).
| Percentage of participants | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | BI 655066 90+180 mg | Stelara |
|---|---|---|---|---|---|
| Week 12 | 67.4 (51.5 to 80.9) | 97.6 (87.1 to 99.9) | 90.5 (77.4 to 97.3) | 94.0 (86.5 to 98.0) | 77.5 (61.5 to 89.2) |
| Week 24 | 55.8 (39.9 to 70.9) | 92.7 (80.1 to 98.5) | 92.9 (80.5 to 98.5) | 92.8 (84.9 to 97.3) | 70.0 (53.5 to 83.4) |
Percentage of participants who achieved 100% reduction from baseline in Psoriasis Area and Severity Index score (PASI100) at Week 12. PASI score ranges from 0 (best) to 72 (worst).
| Percentage of participants | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | BI 655066 90+180 mg | Stelara |
|---|---|---|---|---|---|
| Achievement of 100% Reduction From Baseline in PASI Score (PASI100) at Week 12 | 14.0 (5.3 to 27.9) | 41.5 (26.3 to 57.9) | 50.0 (34.2 to 65.8) | 45.8 (34.8 to 57.1) | 17.5 (7.3 to 32.8) |
Percentage of participants who achieved ≥50% reduction from baseline in Psoriasis Area and Severity Index score (PASI50) at Week 12. PASI score ranges from 0 (best) to 72 (worst).
| Percentage of participants | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | BI 655066 90+180 mg | Stelara |
|---|---|---|---|---|---|
| Achievement of ≥50% Reduction From Baseline in PASI Score (PASI50) at Week 12 | 93.0 (80.9 to 98.5) | 100.0 (91.4 to 100.0) | 95.2 (83.8 to 99.4) | 97.6 (91.6 to 99.7) | 87.5 (73.2 to 95.8) |
Percentage of participants who achieved PASI90 at Week 24. PASI score ranges from 0 (best) to 72 (worst).
| Percentage of participants | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | BI 655066 90+180 mg | Stelara |
|---|---|---|---|---|---|
| Achievement of PASI90 at Week 24 | 30.2 (17.2 to 46.1) | 65.9 (49.4 to 79.9) | 85.7 (71.5 to 94.6) | 75.9 (65.3 to 84.6) | 55.0 (38.5 to 70.7) |
Percentage change in Psoriasis Area and Severity Index (PASI) from baseline at Week 12. PASI score ranges from 0 (best) to 72 (worst).
| Percentage of PASI score | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | BI 655066 90+180 mg | Stelara |
|---|---|---|---|---|---|
| Percentage Change in PASI Score From Baseline at Week 12 | -79.7 ± 19.5 | -93.4 ± 7.7 | -90.7 ± 23.1 | -92.1 ± 17.1 | -82.1 ± 19.5 |
Percentage of participants who achieved static Physician Global Assessment (sPGA) clear or almost clear at Week 12. sPGA is assessed on a six-point scale from 0 (clear) to 5 (severe).
| Percentage of participants | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | BI 655066 90+180 mg | Stelara |
|---|---|---|---|---|---|
| Achievement of sPGA Clear or Almost Clear at Week 12 | 62.8 (46.7 to 77.0) | 90.2 (76.9 to 97.3) | 90.5 (77.4 to 97.3) | 90.4 (81.9 to 95.7) | 67.5 (50.9 to 81.4) |
Time to loss of PASI50 response.
| Days | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | BI 655066 90+180 mg | Stelara |
|---|---|---|---|---|---|
| Time to Loss of PASI50 Response | 253 (212 to 285) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 338 (253 to NA) |
Collected over From first drug administration until 15 weeks after the last drug administration, up to 231 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BI 655066 18 mg | — | 5/43 (11.6%) | 23/43 (53.5%) |
| BI 655066 90 mg | — | 6/41 (14.6%) | 22/41 (53.7%) |
| BI 655066 180 mg | — | 0/42 (0%) | 20/42 (47.6%) |
| Stelara | — | 3/40 (7.5%) | 17/40 (42.5%) |
| Event | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | Stelara |
|---|---|---|---|---|
| BronchitisInfections and infestations | 0/43 | 0/41 | 0/42 | 1/40 |
| DiverticulitisInfections and infestations | 0/43 | 0/41 | 0/42 | 1/40 |
| Urinary tract infectionInfections and infestations | 0/43 | 0/41 | 0/42 | 1/40 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/43 | 1/41 | 0/42 | 0/40 |
| Acute myocardial infarctionCardiac disorders | 0/43 | 1/41 | 0/42 | 0/40 |
| Coronary artery occlusionCardiac disorders | 0/43 | 1/41 | 0/42 | 0/40 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/43 | 1/41 | 0/42 | 0/40 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/43 | 1/41 | 0/42 | 0/40 |
| Salivary gland neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 1/41 | 0/42 | 0/40 |
| Cerebrovascular accidentNervous system disorders | 0/43 | 1/41 | 0/42 | 0/40 |
| Event | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | Stelara |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 15/43 | 14/41 | 11/42 | 5/40 |
| HeadacheNervous system disorders | 5/43 | 2/41 | 3/42 | 4/40 |
| SinusitisInfections and infestations | 1/43 | 0/41 | 1/42 | 4/40 |
| GastroenteritisInfections and infestations | 1/43 | 4/41 | 0/42 | 0/40 |
| Back painMusculoskeletal and connective tissue disorders | 2/43 | 4/41 | 1/42 | 1/40 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/43 | 1/41 | 3/42 | 3/40 |
| PsoriasisSkin and subcutaneous tissue disorders | 3/43 | 1/41 | 0/42 | 3/40 |
| RhinitisInfections and infestations | 0/43 | 3/41 | 1/42 | 1/40 |
| Upper respiratory tract infectionInfections and infestations | 0/43 | 3/41 | 1/42 | 1/40 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/43 | 2/41 | 3/42 | 2/40 |
Safety Set (SAF) which Included all randomised patients who received at least 1 dose of trial medication and was based on the first treatment received.
| Age, Continuous(Years) | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | Stelara | Total |
|---|---|---|---|---|---|
| Mean | 44.1 ± 14.2 | 49.3 ± 13.3 | 44.9 ± 14.0 | 45.4 ± 12.1 | 45.9 ± 13.5 |
| Sex: Female, Male(Participants) | BI 655066 18 mg | BI 655066 90 mg | BI 655066 180 mg | Stelara | Total |
|---|---|---|---|---|---|
| Female | 20 | 11 | 13 | 13 | 57 |
| Male | 23 | 30 | 29 | 27 | 109 |
The record gives a start of Feb 2014, a primary completion of Nov 2014 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab